5P Comparison of PD-L1 expression before and after neoadjuvant chemoradiation or chemotherapy in stage III non-small cell lung cancer (NSCLC)

Abstract

The incorporation of immune-checkpoint inhibitors (ICIs) into the multimodal treatment of stage III NSCLC is likely to change future treatment standards. PD-L1 protein expression on tumor and/or immune cells has emerged as the first predictive biomarker for sensitivity to ICIs targeting the PD-1/PD-L1 axis. Little is known on the impact of treatment modalities such as chemotherapy (CT), radiotherapy (RT) and/or combinations on PD-L1.